AccurKardia vs Ceribell (2026)
Both use cleared machine learning to read a physiological signal, and they serve different specialties. AccurKardia is software for cardiac monitoring: AccurECG interprets ambulatory ECG recordings beat by beat across 13 rhythm classes, taking recordings from other makers' patches and Holter monitors, under two FDA 510(k) clearances. Ceribell is a point of care EEG system for emergency departments and ICUs. A headband and recorder go on in minutes, the Clarity algorithm reads the EEG every ten seconds to estimate seizure burden and alert at the bedside to suspected status epilepticus, and a second model monitors features associated with delirium. Its seizure detection is cleared for adults, children from one year, and preterm neonates. They are rarely alternatives. AccurKardia fits a cardiac monitoring service; Ceribell fits a hospital that cannot get conventional EEG read quickly.
- Software that interprets ambulatory ECG recordings from other makers' devices.
- Detection of 13 rhythm classes, including atrial fibrillation and ventricular tachycardia.
- Sold to monitoring companies, device makers, hospitals and testing facilities.
- A headband EEG placed in minutes where conventional EEG is not at hand.
- A machine learning algorithm estimating seizure burden every ten seconds, with bedside alerts.
- Delirium monitoring cleared in December 2025, and neurologists reviewing recordings remotely.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AccurKardia and Ceribell are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AccurKardia | Ceribell |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2019 | 2014 |
| Headquarters | New York, New York, United States | Sunnyvale, California, United States |
| Website | accurkardia.com | ceribell.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Ceribell
-
Regulatory / FDA
Ceribell received FDA 510(k) clearance (K261712) for software that adds Alpha Delta Ratio and Relative Alpha trending, burst suppression monitoring and amplitude integrated EEG to its point of care EEG system.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
AccurKardia makes AccurECG, cloud based software for automated interpretation of ambulatory ECG recordings, sold to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities.
Source: AI Health Index, September 2026
Point-of-care EEG company (NASDAQ: CBLL) whose headband and recorder can be placed in minutes in emergency departments and ICUs where conventional EEG and neurology reading are not immediately available. Its Clarity machine learning algorithm reads the EEG every ten seconds to estimate seizure burden and alert at the bedside to suspected status epilepticus, and a second model monitors EEG features associated with delirium; neurologists review recordings remotely through a web and mobile portal.
Source: AI Health Index, September 2026
Questions buyers ask
How are AccurKardia and Ceribell priced and sold?
For AccurKardia, the company sells interpretation software to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities, and describes version 2.0 as built to process high volume ECG streams at lower cost; its site links terms of use.
With Ceribell, the annual report says revenue comes from single-patient headbands and a monthly subscription fee for Clarity, recorders and the portal; the published purchase terms describe purchased and loaned recorders (with a $2,500 charge for a lost or damaged loaned recorder), subscription terms and headband warranties. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do AccurKardia and Ceribell cover?
In AccurKardia's case, the version 2.0 indication covers adults 22 and older prescribed outpatient cardiac monitoring for up to ten days, single lead recordings from wet silver chloride electrodes, assessed by qualified healthcare professionals in office or clinical settings, across 13 rhythm classifications, which is narrow and supported by FDA review.
For Ceribell, the system is for acute care: emergency departments, adult ICUs, pediatric ICUs and neonatal ICUs, where conventional EEG and neurology reading are not immediately available. Seizure detection is cleared for adults, for patients aged one and older, and for preterm neonates from 25 weeks, each on its own validation data, and delirium monitoring has its own clearance. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither company publishes a price.
Ask both how often their algorithm flags an event that a specialist reviewer later rejects.